Rapamycin promotes β-amyloid production via ADAM-10 inhibition
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Rapamycin is a well known immunosuppressant drug for rejection prevention in organ transplantation. Numerous clinical trials using rapamycin analogs, involving both children and adults with various disorders are currently ongoing worldwide. Most recently, rapamycin gained much attention for what appears to be life-span extending properties when administered to mice. The risk for Alzheimer disease (AD) is strongly and positively correlated with advancing age and is characterized by deposition of β-amyloid peptides (Aβ) as senile plaques in the brain. We report that rapamycin (2.5 μM), significantly increases Aβ generation in murine neuron-like cells (N2a) transfected with the human “Swedish” mutant amyloid precursor protein (APP). In concert with these observations, we found rapamycin significantly decreases the neuroprotective amino-terminal APP (amyloid precursor protein) cleavage product, soluble APP-α (sAPP-α) while increasing production of the β-carboxyl-terminal fragment of APP (β-CTF). These cleavage events are associated with decreased activation of a disintegrin and metallopeptidase domain-10 (ADAM-10), an important candidate α-secretase which opposes Aβ generation. To validate these findings in vivo, we intraperitoneal (i.p.) injected Tg2576 Aβ-overproducing transgenic mice with rapamycin (3 mg/kg/day) for 2 weeks. We found increased Aβ levels associated with decreased sAPP-α at an average rapamycin plasma concentration of 169.7 ± 23.5 ng/mL by high performance liquid chromatography (HPLC). These data suggest that although rapamycin may increase the lifespan in some mouse models, it may not decrease the risk for age-associated neurodegenerative disorders such as AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“[10,11]”
RetractedRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“Of particular note, the treatment began in mice aged 20 months, the human equivalent of 60 years.[14] This suggests the possibility of an effective anti-aging treatment for humans at an already-advanced age, as opposed to requiring a lifelong regimen beginning in youth.”
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“[1,2,3,4] The hypothesis is supported by the identification of familial mutations of APP (amyloid precursor protein) and presenilins (PS-1,2).[5,6,7,8] These mutations lead to increased generation of the amyloid-beta (Aβ); and especially the 42-amino acid form (Aβ1–42) displays an increased propensity for aggregation…”
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“Intramembranously, β-CTF is then cleaved by a multiprotein γ-secretase complex that results in generation of the Aβ peptide and smaller γ-CTF.[25,26] Conversely, in the nonamyloidogenic pathway, APP is first cleaved at the α-secretase site, which results in the release of N-terminal sAPP-α and the generation of α-CTF…”
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“[1,2,3,4] The hypothesis is supported by the identification of familial mutations of APP (amyloid precursor protein) and presenilins (PS-1,2).[5,6,7,8] These mutations lead to increased generation of the amyloid-beta (Aβ); and especially the 42-amino acid form (Aβ1–42) displays an increased propensity for aggregation…”
Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 1×
“[23] However, despite these findings, and the anti-inflammatory effects of rapamycin which may delay aging processes and enhance clearance mechanisms (autophagy) in certain mice, rapamycin-associated Aβ generation may ultimately prevail and lead to increased accumulation of toxic small oligomeric Aβ species as clearan…”
Structural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783 · cited 1×
“[9] More recently, it has been suggested that accumulation of smaller toxic oligomers of Aβ may be more relevant than plaques to mechanisms involved in neurodegeneration and cognitive decline.[10,11]”
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Self-citationRapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng, L., Xu, L., Gutmann, D. H., & Wong, M. (2008) · Annals of Neurology · doi:10.1002/ana.21331 · Cited by 639 · cited 2×
“[21] Rapamycin was administered based on a treatment schedule that produces benefit in a tuberous sclerosis mouse model (3mg/kg).[18] Tg2576 mice at 4 months of age were i.”
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481 · cited 1×
“However, unlike the tacrolimus-FKBP12 complex which inhibits calcineurin (PP2B), the rapamycin-FKBP12 complex inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex-1 (mTORC-1).[12,30] Combination therapy with doxorubicin and rapamycin has been shown to drive Akt-positive lympho…”
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice
Tan, J., Town, T., Crawford, F., Mori, T., DelleDonne, A., Crescentini, R., Obregon, D., Flavell, R. A., & Mullan, M. J. (2002) · Nature Neuroscience · doi:10.1038/nn968 · Cited by 217 · cited 2×
“[20] All antibodies were diluted in TBS containing 5% (w/v) nonfat dry milk.”
Self-citationThe immunosuppressant rapamycin exacerbates neurotoxicity of Aβ peptide
Lafay‐Chebassier, C., Pérault‐Pochat, M. C., Page, G., Bilan, A. R., Damjanac, M., Pain, S., Houeto, J., Gil, R., & Hugon, J. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21039 · Cited by 52
Cited by
Lipton, J. O., & Sahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 736
Fighting neurodegeneration with rapamycin: mechanistic insights
Bové, J., Martínez-Vicente, M., & Vila, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3068 · Cited by 525
Wang, I.-F., Guo, B.-S., Liu, Y.-C., Wu, C.-C., Yang, C.-H., Tsai, K.-J., & Shen, C.-K. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206362109 · Cited by 377
“Such negative outcomes of the use of rapamycin as a therapeutic agent have also been found in other Alzheimer’s disease animal models (26, 27, 34).”
BackgroundMammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
Autophagic/lysosomal dysfunction in Alzheimer’s disease
Orr, M. E., & Oddo, S. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt217 · Cited by 199
“ment in Tg2576 AD mice increased Aβ [65].”
Background
Metadata
- Authors
- Zhang, S., Salemi, J., Hou, H., Zhu, Y., Mori, T., Giunta, B., Obregon, D., & Tan, J.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 398
- Issue
- 3
- Pages
- 337-341
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2042879928
- Cited by
- 61
- References
- 13
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.